A Phase I/II, Dose-Escalation and Dose-Expansion Study of CS5006, in Participants With Advanced Solid Tumors
A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activities of CS5006, a Novel Antibody-Drug Conjugate Targeting ITGB4, in Participants With Advanced Solid Tumors
This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS5006 in participants with advanced solid tumors. The study comprises of a Phase I dose escalation and Phase II dose expansion.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
In Phase I, participants with specified advanced epithelial solid tumors will be enrolled to establish the MTD, if any, and tentative RP2D(s) of CS5006. The specified advanced epithelial solid tumors included but not limited non-small cell lung cancer (NSCLC), colorectal cancer (CRC), squamous cell carcinoma of head and neck (HNSCC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), cervical cancer (CC), esophageal squamous cell carcinoma (ESCC) , endometrial cancer, ovarian cancer (OC), renal cell carcinoma (RCC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), biliary tract cancer (BTC), gastric cancer (GC), pancreatic cancer(PDAC) and prostate cancer(PCa).
In Phase II, participants with selected advanced solid tumors - including locally advanced or metastatic non-small cell lung cancers (AGA [actionable genomic alterations] negative NSCLC, Cohort 1; EGFR-mutant NSCLC, Cohort 2; NSCLC with actionable driver alterations other than EGFR-sensitive mutations, Cohort 3; colorectal cancer (CRC), Cohort 4; squamous cell carcinoma of head and neck (HNSCC), Cohort 5; urothelial carcinoma (UC), Cohort 6; cervical cancer (CC), Cohort 7; esophageal squamous cell carcinoma (ESCC), Cohort 8 - will be enrolled to further assess the efficacy, safety, tolerability, pharmacokinetics of CS5006 at the tentative RP2D(s).
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Crystal Wang
- Número de teléfono: +86-021-60332455
- Correo electrónico: wangjingru@cstonepharma.com
Ubicaciones de estudio
-
-
New South Wales
-
North Ryde, New South Wales, Australia, 2109
- Macquarie University
-
Investigador principal:
- John Park, Dr
-
Randwick, New South Wales, Australia, 2031
- Scientia Clinical Research Ltd
-
Investigador principal:
- Charlotte lemech, Dr
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Monash Medical Centre
-
Investigador principal:
- Sophia Frentzas, Dr
-
-
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Porcelana, 200123
- Shanghai East Hospital
-
Investigador principal:
- Caicun Zhou
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Evidence of a personally signed and dated informed consent document.
- Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- Being ≥ 18 years of age on the day of signing informed consent.
- Pathologically or cytologically confirmed, unresectable advanced solid tumors.
- Participants must have at least one measurable lesion according to RECIST Version1.1.
- Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1.
- Adequate organ function.
- Life expectancy ≥ 3 months.
- Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 180 days after the last study drug administration
Exclusion Criteria:
- Has disease that is suitable for local treatment administered with curative intent.
- Has a history of a second malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured.
- Known primary central nervous system (CNS) tumor or solid tumor CNS metastasis that is symptomatic, untreated, or requires therapy.
- Has life-threatening bleeding event or severe bleeding within 3 months prior to first dose.
- Has uncontrolled pleural effusion, pericardial effusion, or ascites.
- Has immune deficient disease or received systemic immunosuppressive treatment.
- Has intestinal obstruction,or history of inflammatory bowel disease,or chronic diarrhea.
- Has history of (non-infectious) interstitial lung disease/pneumonitis that required steroids.
- Has active infections requiring systemic therapy.
- Has significant cardiovascular disease or cerebrovascular accident within specified timeframes prior to first dose.
- Insufficient washout from prior anti-tumor therapy.
- Received live vaccine within 28 days prior to first dose.
- History of allogeneic organ or hematopoietic stem cell transplantation.
- History of hypersensitivity to excipients of study drug or any monoclonal antibody.
- Any toxic effects of prior therapy unresolved to Grade ≤1.
- Pregnant or breastfeeding women.
- Other acute or chronic medical or psychiatric conditions that may increase risk or interfere with study results, in the investigator's judgment.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Dose Escalation
Participants will be administered escalating doses of CS5006. |
CS5006 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W). |
|
Experimental: Dose Expansion
Participants will be administered the recommended dose(s) of CS5006 according to dose-escalation data. |
CS5006 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W). |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
[Expansión de dosis] Tasa de respuesta objetiva (TRO) evaluada por investigadores según RECIST v1.1
Periodo de tiempo: Hasta 2 años aproximadamente
|
Hasta 2 años aproximadamente
|
|
|
[Dose Escalation] The incidence and severity of adverse events (AEs)
Periodo de tiempo: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
[Dose Escalation] Maximum tolerated dose (MTD) of CS5006
Periodo de tiempo: Cycle 1 (Up to 21 Days)
|
Participants will receive CS5006 via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W). The MTD will be determined, if any, by the number of participants who experience a dose limiting toxicity (DLT). |
Cycle 1 (Up to 21 Days)
|
|
[Dose Escalation] Tentative recommended Phase II dose (RP2D) of CS5006
Periodo de tiempo: Up to approximately 2 years
|
The selection of tentative RP2D will be based on consideration of overall safety information together with available pharmacokinetic, pharmacodynamic, and efficacy data. The tentative RP2D may be the MTD or a lower dose within the tolerable dose range. |
Up to approximately 2 years
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
[Aumento de dosis] Tasa de respuesta objetiva (TRO) evaluada por investigadores según RECIST v1.1
Periodo de tiempo: Hasta 2 años aproximadamente
|
Hasta 2 años aproximadamente
|
|
[Dose Escalation & Expansion] Area under the curve (AUC) of CS5007
Periodo de tiempo: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Duration of response (DOR) evaluated by investigators per RECIST v1.1
Periodo de tiempo: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Disease control rate (DCR) evaluated by investigators per RECIST v1.1
Periodo de tiempo: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Expansion] The incidence and severity of adverse events (AEs)
Periodo de tiempo: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Maximum concentration (Cmax) of CS5006
Periodo de tiempo: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Time to maximum concentration (Tmax) of CS5006
Periodo de tiempo: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Elimination half-life (t1/2) of CS5006
Periodo de tiempo: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Clearance (CL) of CS5006
Periodo de tiempo: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Volume of distribution (Vz) of CS5006
Periodo de tiempo: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Trough concentration (Ctrough) of CS5006
Periodo de tiempo: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Accumulation ratio (R) of CS5006
Periodo de tiempo: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Number of participants with anti-CS5006 antibodies
Periodo de tiempo: Up to approximately 2 years
|
Up to approximately 2 years
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
Otros números de identificación del estudio
- CS5006-101
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .